April delivered no shortage of turbulence — but also a few genuine bright spots. Amid ongoing instab...

Commentary on everything related to cryo-EM in drug discovery.
April delivered no shortage of turbulence — but also a few genuine bright spots. Amid ongoing instab...
Clovertex’s March Target of the Month is GSPT1, a translation termination factor that plays a vital ...
This month, Cryo-EM provided new insights into the vitamin K enzyme, as well as channel and GPCR str...
Clovertex's February Target of the Month is the farnesoid X receptor (FXR), a nuclear receptor that ...
Submit your research abstracts for the upcoming Proteros-sponsored International Biostructure Associ...
In the world of structural biology, few tools have had as profound an impact as scFv16. This single-...
This month’s top posts, grouped by platform (Bluesky, X, and LinkedIn), showcase the latest cryo-EM ...
Clovertex’s January Target of the Month is Dopamine D2 Receptor (D2R), highlighted by Johnson & John...
Cryo-EM Twitter used to be an incredible place - a scientific hub chipping away at many of academia’...
Clovertex’s Target of the Year 2024 is the Gastric Inhibitory Polypeptide Receptor (GIPR), which has...